ASSOCIATION GENE APOE WITH CLINICAL AND ANAMNESTIC CHARACTERISTICS Of SEVERITY ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

Purpose. To evaluate the association between polymorphisms APOE rs7412+rs429358 and traditional risk factors for CHD in patients with myocardial infarction with ST-segment elevation.

Materials and Methods. 358 patients admitted with STEMI and undergoing diagnosis and treatment at the Kemerovo Cardiology Clinic were included in the study. Blood samples were collected at days 2–14 for genotyping. Clinical and demographic data, laboratory and instrumental findings were assessed. Data analysis was performed using the STATISTICA program (version 8.0; StatSoft, Tulsa, Oklahoma) and SPSS Statistics 17.0.

Results. The carriers of the e4 allele of gene APOE was associated with adverse anamnestic characterisics, such as myocardial infarction in anamnesis, severe chronic heart failure and prior angina. The carriers of the e4 allele had a higher level of LDL and severe coronary arterial sclerotic disease (SYNTAX ≥23 score (OR=2.10, 95 % CI=1.26–3.51, p=0.005). The carriers of the e4 allele had signs of multifocal atherosclerosis (OR=2.44, 95 % CI=1.17–5.12, p=0.02) and reduction of left ventricular ejection fraction less 40 % (OR=5.25, 95 % CI=1.06–27.39, p=0.04).

Conclusion. Was demonstrated, that gene APOE associated not only with lipid metabolism disorders, but also to the clinical criteria of severe STEMI and can to be used as a marker adverse clinical progression of STEMI.

1. Оганов Р. Г. Профилактика сердечно-сосудистых заболеваний: руководство. М.; 2009. Oganov R. G. Profilaktika serdechno-sosydistih zabolevanii: rukovodstvo. Moscow; 2009.

2. Гарганеева А. А., Округин С. А., Ефимова Е. В., Борель К. Н. «Регистр острого инфаркта миокарда» как информационная популяционная система оценки эпидемиологической ситуации и медицинской помощи больным острым инфарктом миокарда. Сердце. 2013; 1: 37–41. Garganeeva A. A., Okrugin S. A., Efimova E. V., Borel K. N. Registr ostrogo infarcta miokarda kak informacionnaya populyationnaya systema ocenki epidemiologicheskoi sityacii i medicinskoi pomoshi bolnim ostrim infarctom miocarda. Serdce. 2013; 1: 37–41.

3. Барбараш О. Л., Карташян Э. С., Кашталап В. В., Бернс С. А., Ганюков В. И., Евтушенко С. А. и др. Распространенность и клинико-прогностическая значимость «непораженных» коронарных артерий у больных с острым коронарным синдромом. Кардиоваскулярная терапия и профилактика. 2011; 1: 47–52. Barbarash O. L., Kartashyan E. S., Kashtalap V. V., Berns S. A., Ganyukov V. I., Evtushenko S. A. et al. Prevalence and clinical and prognostic value of «intact» coronary arteries in patients with acute coronary syndrome. Cardiovascular therapy and prevention. 2011; l: 47–52. [In Russ.].

4. Хурс Е. М., Поддубная А. В. Эхокардиография в диагностике структурно- функционального состояния и ремоделирования сердца. Ультразвуковая и функциональная диагностика. 2010; 1: 89–100. Khurs E. M., Poddubnaya A. V. Echocardiography in the Diagnosis of a Structural and Functional Cardiac State and Cardiac Remodeling. Ultrasound and functional diagnostics. 2010; 1: 89–100. [In Russ.].

5. Peterson E. D., Shaw L. J., Califf R. M. Clinical Guideline: Part II: Risk stratification after myocardial infarction. Ann. Intern. Med. 1997; 126: 561–582. PMID: 9092324.

6. Климов А. Н., Никульчева Н. Г. Обмен липидов и липопротеидов и его нарушения. СПб.; 1999. Klimov A. N., Nikulicheva N. G. Obmen lipidov i lipoproteinov i ego narusheniya. St. Peterburg; 1999.

7. Singh P. P., Singh M., Mastana S. S. APOE distribution in world populations with new data from India and the UK. Аnn. Hum. Biol. 2006; 33: 279–308. PMID: 17092867.

8. Tisko R., Sopkova Z., Habalova V., Dorkova Z., Slaba E., Javorsky M. et al. Effects of apolipoprotein E genotype on serum lipids in obstructive sleep apnoea. Eur. Respir. J. 2014; 43: 1097–1105. DOI: 10.1183/09031936.00098513.

9. Hu M., Mak V. W., Tomlinson B. Polymorphisms in apolipoprotein E and apolipoprotein A- V do not influence the lipid response to rosuvastatin but are associated with baseline lipid levels in Chinese patients with hyperlipidemia. J. Clin. Lipidol. 2012; 6: 585–592. DOI: 10.1016/j.jacl.2012.02.005.

10. Lee M. J., Chien K. L., Chen M. F., Stephenson D. A., Su T. C. Overweight modulates APOE and APOA5 alleles on the risk of severe hypertriglyceridemia. Clin. Chim. Acta. 2013; 1: 31–35. DOI: 10.1016/j.cca.2012.10.054.

11. Huang H., Liu J., Feng Y., Chen W. The distribution of apolipoprotein E gene polymorphism in Chinese civil aircrews, and a possible risk factor to their overweight and dyslipidemia is cumulative flight time. Clin. Chim. Acta. 2013; 1: 36–40. DOI: 10.1016/j.cca.2012.10.049.

12. Топчиева Л. В., Рендаков Н. Л., Коломейчук С. Н., Гуров Э. В., Корнева В. А., Малышева И. Е. Роль полиморфных вариантов гена АРОЕ в развитии сердечно- сосудистых заболеваний у жителей Республики Карелия. Ученые записки Петрозаводского государственного университета. Сер.: Естественные и технические науки. 2011; 4: 54–57. Topchieva L. V., Rendakov N. L., Kolomeichuk S. N., Gurov E. V., Korneeva V. A., Malysheva I. E. Role polymorphnih variantov gena APOE v razvitii serdechno-sosydistih zabolevanii u gitelei Respubliki Karelia. Uchenie zapiski Petrozavodskogo gosudarstvennogo universiteta. Ser: Estestvennie i tehnicheskie nauki. 2011; 4: 54–57.

13. Tyynela P., Goebeler S., Ilveskoski E., Mikkelsson J., Perola M., Lehtimaki T. et al. Age- dependent interaction of apolipoprotein E gene with eastern birthplace in Finland affects severity of coronary atherosclerosis and risk of fatal myocardial infarction – Helsinki Sudden Death Study. Ann. Med. 2013; 45: 213–219. DOI: 10.3109/07853890.2012.727021.

14. Yin Y. W., Sun Q. Q., Zhang B. B., Hu A. M., Liu H. L., Wang Q. et al. Association between apolipoprotein E gene polymorphism and the risk of coronary artery disease in Chinese population: evidence from a meta-analysis of 40 studies. PLoS One. 2013; 8: 233–241. DOI: 10.1371/journal.pone.0066924.

15. Grammer T. B., Hoffmann M. M., Scharnagl H., Kleber M. E., Silbernagel G., Pilz S. et al. Smoking, apolipoprotein E genotypes, and mortality (the Ludwigshafen Risk and Cardiovascular Health study). Eur. Heart J. 2013; 34: 1298– 1305. DOI: 10.1093/eurheartj/eht001.

16. Maxwell T. J., Ballantyne C. M., Cheverud J. M., Guild C. S., Ndumele C. E., Boerwinkle E. APOE modulates the correlation between triglycerides, cholesterol, and CHD through pleiotropy, and gene-by-gene interactions. Genetics. 2013; 195: 1397–1405. DOI: 10.1534/genetics.113.157719.

17. Eto M., Saito M. Familial type III hyperlipoproteinemia. Nihon Rinsho. 2013; 71: 1590–-1594.

18. Mahfouz R. A., Charafeddine K. M., Tanios R. F., Karaky N. M., Abdul Khalik R. N., Daher R. T. Apolipoprotein E gene polymorphisms in Lebanese with hypercholesterolemia. Gene. 2013; 10: 84–88. DOI: 10.1016/j.gene.2013.03.019.

19. Evans D., Beil F. U., Aberle J. Resequencing the APOE gene reveals that rare mutations are not significant contributory factors in the development of type III hyperlipidemia. J. Clin. Lipidol. 2013; 7: 671–674. DOI: 10.1016/j.jacl.2013.05.003.

20. Xu H., Li H., Liu J., Zhu D., Wang Z., Chen A. et al. Meta-analysis of apolipoprotein E gene polymorphism and susceptibillity of myocardial infarction. PloS One. 2014; 9: 374–383. DOI: 10.1371/journal.pone.0104608.